New research indicates that patients who discontinue popular GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds much more quickly than those who stop conventional lifestyle programs.
Findings released in a leading health publication demonstrates that while overweight individuals often shed substantial amounts of their body weight while undergoing treatment, the mass returns at an average rate of nearly a kilo each month once they quit.
"Individuals using these drugs should be informed of the danger of quick rebound weight gain when the medication concludes," cautioned expert Dr. Susan Jebb.
This pace of recovery means a reversion to starting weight within about 18 months.
Weighing Approaches
The analysis, which examined dozens of studies involving thousands of participants, compared the outcomes of GLP-1 agonists with conventional dieting.
Researchers emphasize that individuals who shed pounds through lifestyle changes alone typically see a slower creep back—around 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Experts believe the way of the injections accounts for the accelerated weight return.
These medications mimic a natural hormone called glucagon-like peptide-1, which controls hunger.
"Long-term administration of the hormone concentrations far above than normal might result in the body to produce less of its own natural hormone, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement means appetite is uncontrolled, making overeating much more probable."
An Ongoing Disease?
Medical guidelines recommend the injections for people with weight-linked medical conditions, alongside prescribed lifestyle changes.
Professionals contend that, considering the significant potential of weight regain, the therapy should be considered life-long.
This opinion is echoed by pharmaceutical companies, who say that the findings "underscore the persistent nature of obesity," comparing it to managing diseases like hypertension.
User Experiences
People who have discontinued the jabs report a powerful return of hunger.
"I experienced a switch that goes on and you become ravenous," recalled a patient.
This challenge is exacerbated if users have not established lasting lifestyle or habit modifications during therapy.
Widespread Interest
Recent estimates show that millions of people in the UK have tried these injections in the last 12 months, with demand continuing to grow.
- Adoption is higher among females than males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, clinicians caution that while GLP-1 drugs are powerful agents for weight loss, they are not a magic fix and lasting health benefits likely depends on integrated lifestyle changes.
